Licence granted in UK for injectable methotrexate

Medac has launched the first UK-licenced methotrexate injection, Metoject, offering a standardised parenteral product for the treatment of rheumatoid arthritis. The injection, licensed for the treatment of severe, active rheumatoid arthritis in adults, removes the problems previously encountered when prescribing parenteral methotrexate for an unlicensed indication or obtaining a supply from a specials manufacturer.

Metoject can be administered by intravenous, intramuscular or subcutaneous injection.

A reduction in dose may be required if changing a patient from oral to parenteral administration due to the variable bioavailability of methotrexate after oral administration.

Metoject, adminstered by subcutaneous injection, was compared to oral methotrexate in a study involving 384 methotrexate naive patients. Both groups were given 15mg once weekly and evaluated according to criteria set by the American College of Rheumatology that includes joint mobility, pain and radiographic changes.

After 24 weeks, 78% of the subcutaneous administration group showed a 20% improvement in clinical symptoms and 34% achieved remission of symptoms. This compares favourably to the oral administration group in which 67% of patients showed a 20% improvement in clinical symptoms and 24% achieved remission of symptoms.

Further information: Medac 01786 458086

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more